The flow cytometry market is expanding due to increased investment in immuno-oncology and liquid biopsy sectors. With advancements in genome-based research and single-cell analysis, flow cytometry ...

An update from bioAffinity Technologies, Inc. ( ($BIAF) ) is now available. On December 3, 2025, bioAffinity Technologies announced that it will ...

The Global MRD Testing Market is expanding due to rising cancer and hematological malignancy rates and advances in diagnostic tech like next-gen sequencing. Challenges include high costs limiting ...

The work grew out of decades of prostate cancer research by Michael Shen, PhD, co-leader of the Tumor Biology and ...

ACS--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer ...

Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.

The IDEXX Cancer Dx is a new blood-based screening/diagnostic panel aimed at detecting canine lymphoma from serum or whole ...

The SAVE regimen achieved an 86% ORR in newly diagnosed AML, with high MRD-negative rates, especially in NPM1 mutations or KMT2A rearrangements. Significant myelosuppression and infectious ...

In this edition of the biotech bi-weekly, we highlight the latest exciting product launches, partnerships and company events.

Colorectal cancer immunotherapy advances as Photobacterium angustum identified to selectively colonize tumors with minimal systemic toxicity.

Jones anchored her discussion in a core philosophy for veterinary oncology: "one size does not fit all.” According to Jones, ...

Study links anxiety to 74% fewer natural killer cells—immune defenders against cancer and infections. Insomnia intensifies ...